What Is Treatment-Resistant Depression? How to Tell Whether Your Last Two Antidepressants Really Counted

You did what you were told. You took the medication, waited the weeks, maybe tried a second one, and you’re still not better. Somewhere along the way someone used the phrase “treatment-resistant,” and it landed like a verdict.

Here’s what’s happening underneath. Antidepressants work by changing how the brain produces or uses chemicals involved in mood and stress, and NIMH’s medications guide notes they usually take 4 to 8 weeks to work. That means every trial is a test with a dose, a length, and a pass or fail that depends on both. Judging whether depression is truly resistant takes precision, because a trial that was too short or too low can look exactly like a medication that failed.

The standard approach is well established. A World Psychiatry review from 2023 explains that the FDA and EMA use the most common definition: inadequate response to at least two antidepressants despite adequate trials and adherence, a definition at least 30% of people with depression are estimated to meet. The same review describes treatments with established evidence for people who reach that point, including esketamine, TMS, and ECT. The results are real, and the science is well established.

But a label built on two trials is only as reliable as those trials, and at Siggy we think your history deserves an audit before it gets a verdict.

That audit starts with the details: what dose you reached, how long you stayed there, how consistently you took it, why you stopped, and whether anyone measured your symptoms along the way. The World Psychiatry review notes that a significant share of people labeled treatment-resistant are actually pseudo-resistant, often because of inadequate trials or inconsistent use. Sorting that out first is a distinction grounded in pharmacology, and the clinical evidence supports it.

What This Page Covers

• What Does Treatment-Resistant Depression Mean?
• Did Your Past Trials Actually Count?
• Could Something Else Be Going On?
• What Are the Odds With Each New Step?
• Does Closer Tracking Change the Outcome?
• What Comes After Two Antidepressants?
• How Siggy Fits In
• Bring Your Full Medication History to the Next Decision

What Does Treatment-Resistant Depression Mean?

It means depression that hasn’t responded to at least two adequate antidepressant trials. NIMH describes treatment-resistant depression as something that may be diagnosed when symptoms don’t improve after trying at least two antidepressants.

The term is less precise than it sounds. The World Psychiatry review points out that no consensus definition with proven predictive value exists, and that many competing definitions have been proposed. That’s one reason estimates of how common it is vary, and one reason two clinicians may describe the same history differently.

The label means the first-line approach hasn’t been enough and the next decisions deserve more care, and it says nothing about whether other treatments will work.

Did Your Past Trials Actually Count?

This may be the most useful question you can bring to a prescriber. The checklist below draws on the World Psychiatry review’s description of pseudo-resistance, NIMH’s 4 to 8 week timeline, and a U.S. continuity study.

Check	What to Ask	Why It Matters
Dose	Did I reach a full treatment dose?	Low doses can look like failure
Duration	Did I stay on it 4 to 8 weeks or more?	Benefit often takes that long
Consistency	Did I take it most days?	Missed doses weaken a trial
Reason for stopping	Did side effects end it early?	A trial cut short may not count
Measurement	Were symptoms ever scored?	Scores support better decisions

Stopping early is common. In that U.S. study of adults starting an antidepressant for depression, 42.4% stopped within the first 30 days, well before most medications have had time to work. If one of your two trials ended that way, it may not count as a true failure.

Could Something Else Be Going On?

Sometimes the diagnosis needs a second look. FDA labeling for venlafaxine, like other antidepressant labels, tells prescribers to screen for a personal or family history of bipolar disorder, mania, or hypomania before starting, because an antidepressant can trigger a mixed or manic episode in someone with bipolar disorder.

If you’ve ever had stretches of unusually high energy, racing thoughts, or very little need for sleep, say so, even if those periods felt good at the time. Our guide to what causes treatment-resistant depression covers other factors that can make depression harder to treat.

What Are the Odds With Each New Step?

The best-known data come from STAR*D, a large NIMH-funded study that moved people through up to four treatment steps. In the STAR*D outcomes report, self-reported remission rates were 36.8%, 30.6%, 13.7%, and 13.0% at steps one through four, and people who needed more steps had higher relapse rates during follow-up. The authors reported a cumulative remission rate of 67%.

That headline number has been challenged. A 2023 reanalysis of the patient-level data, using the blinded rating scale the original protocol specified and excluding people who already scored as remitted at entry, put cumulative remission at 35%, about half the reported figure.

Both analyses point the same way: each additional trial of a similar medication tends to help fewer people. The World Psychiatry review also describes the evidence for extending a trial, switching medications, or combining antidepressants as mixed. That’s a reason to make every trial count, and to discuss a different kind of treatment rather than cycling through more of the same.

Does Closer Tracking Change the Outcome?

It can. In a measurement-based care trial, a randomized study of 120 outpatients with moderate to severe depression, treatment guided by regular rating scales led to remission in 73.8% of patients, compared with 28.8% for standard care. The measurement group reached remission faster and had more dose adjustments, with no difference in side effects or dropout.

It was a single trial limited to two medications, so the exact numbers shouldn’t be generalized. The principle is still worth taking seriously: decisions made from scored symptoms tend to be better than decisions made from memory at an appointment months apart.

What Comes After Two Antidepressants?

Several paths have evidence behind them. In the VA’s VAST-D trial of 1,522 patients who hadn’t responded to at least one antidepressant, adding aripiprazole led to remission in 28.9% at 12 weeks, compared with 26.9% for adding bupropion and 22.3% for switching to bupropion. The aripiprazole advantage over switching was modest, it came with more sleepiness, restlessness, and weight gain, and the study population was 85% male veterans.

The World Psychiatry review describes the broader options. IV ketamine and esketamine nasal spray are established as effective for treatment-resistant depression, several second-generation antipsychotics help as add-on treatments for partial responders, TMS is established as effective and FDA-approved, and ECT is regarded as effective for both acute and maintenance treatment. NIMH notes that esketamine is given in a provider’s office, clinic, or hospital and often acts within a couple of hours.

Each of these has trade-offs in access, monitoring, and side effects. Our guide to treatment-resistant depression options compares them in more depth, and our post on TMS for treatment-resistant depression covers what that treatment involves.

If depression has left you feeling hopeless or thinking about suicide, call or text 988, or call 911 in an emergency.

How Siggy Fits In

Siggy’s licensed prescribers diagnose and treat the full range of mental health conditions, including depression, and Siggy combines human clinicians with AI therapy and daily check-ins. Siggy doesn’t provide esketamine, ketamine, TMS, or ECT, and those treatments require specialized, in-person care.

Where Siggy can help is the audit. The anonymous intake asks for no name, email, or account, so you can lay out every medication you’ve tried, the doses, how long you took them, and why you stopped, in your own words. A licensed prescriber reviews your full intake before anything is prescribed, and you get a downloadable summary you can bring to a psychiatrist or specialty clinic so the next decision starts from a complete history.

Siggy isn’t an emergency service. If you’re in crisis, call 911 or call or text 988. This article is for education only and isn’t a substitute for personal medical advice. It reflects sources available as of October 2026.

Bring Your Full Medication History to the Next Decision

Treatment-resistant depression is a real and common problem, but the label is only as solid as the trials behind it, and a careful look at dose, duration, consistency, and diagnosis sometimes changes the picture. When true resistance is confirmed, effective options still exist, and the odds improve when each step is measured and deliberate. If your most recent antidepressant has stalled, our 8-week decision path walks through what usually comes next. Start your anonymous intake and list everything you’ve tried and how it went. It’s free, a real doctor reviews every clinical decision, and the summary is yours to share with whoever helps you next.